Azintuxizumab vedotin

Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells[1].

Product Specifications

CAS Number

[1826819-58-2]

Product Name Alternative

ABBV-838

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs)

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/azintuxizumab-vedotin.html

Purity

98.55

Solubility

H2O

Smiles

[Azintuxizumabvedotin]

Molecular Weight

(146.036 kDa)

References & Citations

[1]Vij R, et al. First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clin Cancer Res. 2020 May 15;26 (10) :2308-2317.